CytoMed Therapeutics - GDTC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 140.38%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.08
▲ +0.02 (0.97%)

This chart shows the closing price for GDTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CytoMed Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GDTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDTC

Analyst Price Target is $5.00
▲ +140.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CytoMed Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 140.38% upside from the last price of $2.08.

This chart shows the closing price for GDTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in CytoMed Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00 ➝ $5.00Low
12/4/2023BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00Low
7/21/2023BenchmarkInitiated CoverageBuy$5.00Low
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
CytoMed Therapeutics logo
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.
Read More

Today's Range

Now: $2.08
Low: $2.08
High: $2.08

50 Day Range

MA: $2.09
Low: $1.95
High: $2.25

52 Week Range

Now: $2.08
Low: $1.92
High: $9.25

Volume

1,365 shs

Average Volume

22,112 shs

Market Capitalization

$22.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of CytoMed Therapeutics?

The following Wall Street research analysts have issued reports on CytoMed Therapeutics in the last year: Benchmark Co..
View the latest analyst ratings for GDTC.

What is the current price target for CytoMed Therapeutics?

1 Wall Street analysts have set twelve-month price targets for CytoMed Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 140.4%. Benchmark Co. has the highest price target set, predicting GDTC will reach $5.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $5.00 for CytoMed Therapeutics in the next year.
View the latest price targets for GDTC.

What is the current consensus analyst rating for CytoMed Therapeutics?

CytoMed Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GDTC will outperform the market and that investors should add to their positions of CytoMed Therapeutics.
View the latest ratings for GDTC.

What other companies compete with CytoMed Therapeutics?

How do I contact CytoMed Therapeutics' investor relations team?

The company's listed phone number is 65-6250-7738. The official website for CytoMed Therapeutics is w2.cytomed.sg. Learn More about contacing CytoMed Therapeutics investor relations.